BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies. In addition to cancer peptide vaccines currently in clinical trials in Japan and the United States, BrightPath is actively involved in developing cell therapies, immunomodulatory antibodies and new drugs targeted at cancer specific neoantigens.


Masashi Fukuari Leader, Business Development, Pharmaceutical Development Phone: +81-3-5804-7697
Tadashi Mori Manager, R&D Planning / Business Development Phone: +81-3-5804-7697
Kojimachi Central Building 7F, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo